Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 2/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.30 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1099645 | 0.97 | — | — | |
| SCHEMBL8225505 | 0.97 | — | — | |
| SCHEMBL12715 | 0.97 | — | — | |
| SCHEMBL22580339 | 0.94 | SMN1; SMN2 (0.42) | SMN1; SMN2CXCR4ALDH1A1TSHRNOS2 | |
| SCHEMBL7976940 | 0.91 | — | — | |
| SCHEMBL7965486 | 0.89 | — | — | |
| SCHEMBL23938465 | 0.88 | SMN1; SMN2 (0.39) | SMN1; SMN2CXCR4ALDH1A1TSHRCYP2C9 | |
| Piperazine SCHEMBL317436 | 0.88 | HIF1A (0.43) | SMN1; SMN2CXCR4TSHRCYP2C9CYP2C19 | |
| SCHEMBL21250630 | 0.86 | ALDH1A1 (0.47) | SMN1; SMN2CXCR4ALDH1A1NOS2 | |
| SCHEMBL18849939 | 0.86 | ALDH1A1 (0.47) | SMN1; SMN2CXCR4ALDH1A1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10300075-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2019-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10300075-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | SMN1; SMN2 1842/4885CXCR4 2449/4885ALDH1A1 1575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.